AI assistant
BP PLC — Share Issue/Capital Change 2018
Dec 20, 2018
4622_rns_2018-12-20_2ce21d53-2ac8-499b-bc14-8368f160d4cc.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1676L
BP PLC
20 December 2018
20 December 2018
BP p.l.c.
Share issuance
BP p.l.c. announces that on 21 December 2018 it will issue and allot 50,000,004 ordinary shares in connection with distributions to participants in certain of its employee share schemes. The issuance of the new ordinary shares is subject to an application for the admission of those shares to the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange plc ("Admission"). It is expected that Admission will occur on 21 December 2018.
Following the allotments for scrip dividend programme announcement released earlier today (RNS no. 1655L), the number of ordinary shares in issue after this admission will be 21,525,464,027 of which 1,370,884,510 are held as treasury shares leaving a balance of 20,154,579,517 ordinary shares with a par value of US$0.25 per share, each with one vote and 12,706,252 preference shares par value £1 per share with two votes for every £5 in nominal capital held and the total number of voting rights in BP p.l.c. will be 20,159,662,017.
These new ordinary shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of US$0.25 each in BP p.l.c., including the right to receive dividends and other distributions declared, made or paid on or in respect of such shares after the date of issue.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
ALSLLFVSFELIFIT